An investigation towards understanding the role of CDH1 gene in different types of Breast Cancers

Mapping Intimacies ◽

10.1101/2021.01.11.426236 ◽

2021 ◽

Author(s):

Antara Sengupta ◽

Raja Banerjee

Keyword(s):

Breast Cancer ◽

Potential Role ◽

Regular Function ◽

Breast Cancers ◽

Cdh1 Gene ◽

Different Types ◽

Genetic Aberration ◽

Breast Tissues

AbstractAt recent age breast cancer attracts the attention of both the medical and the scientific community for its deadly occurrence throughout the globe as it is considered to be happened due to genetic aberration. Out of several genes expressed, it is found that cadherin 1, type 1 (CDH1) is responsible in several ways to control the metabolic order in human. Hence we focus on CDH1 gene whether any deviation in it especially alteration/modification in its sequence is responsible for the occurrence of this deadly disease. Towards this end study of the available genomic sequences of CDH1 gene of several patients, suffering from various types of breast cancer (obtained from the Sanger Database), are studied. The results emphasizes that alternation/modification in the sequence of the CDH1 gene affect its regular function which may have a potential role in damaging the different types of breast tissues, causing malfunction and leading to breast cancers in patients.

Download Full-text

An Investigation Towards Understanding the Role of CDH1 Gene in Different Types of Breast Cancers

10.21203/rs.3.rs-578951/v1 ◽

2021 ◽

Author(s):

Antara Sengupta ◽

Raja Banerjee

Keyword(s):

Breast Cancer ◽

Regular Function ◽

Breast Cancers ◽

Cdh1 Gene ◽

Root Cause ◽

Different Types ◽

Genetic Aberration ◽

Breast Tissues

Abstract At recent age breast cancer attracts the attention of both the medical and the scientific community for its deadly occurrence throughout the globe as it is considered to be happened due to genetic aberration. Out of several genes expressed, it is found that cadherin 1, type 1 (CDH1) is responsible in several ways to control the metabolic order in human. Very recently it has been shown that deregulation of the function of protein E-cadherin, expressed from CDH1 plays an important role in lobular breast cancer. In order to understand the root cause of this recent claim, we focus on CDH1 gene whether the genetic information translated due to any deviation/alteration/modification in its sequence is related for the occurrence of the several other types of this deadly disease. Towards this end, study of the available genomic sequences of CDH1 gene obtained from the Sanger Database for 79 patients, suffering from various types of breast cancer, clearly emphasizes that alternation/modification in the sequence of the CDH1 gene can be detrimental. This would affect the regular function of the cell which may have a potential role in damaging the different types of breast tissues, causing malfunction and leading to breast cancers.

Download Full-text

ER81 Expression in Breast Cancers and Hyperplasia

Pathology Research International ◽

10.4061/2011/980513 ◽

2011 ◽

Vol 2011 ◽

pp. 1-6 ◽

Cited By ~ 10

Author(s):

YuanYuan Wang ◽

Li Wang ◽

Yue Chen ◽

Lin Li ◽

XuanTao Yang ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Statistical Significance ◽

Normal Breast ◽

Breast Development ◽

Breast Cancers ◽

Breast Carcinogenesis ◽

Cancer Tissues ◽

Breast Tissues

ER81 is a transcription factor that may contribute to breast cancer; however, little known about the role of ER81 in breast carcinogenesis. To investigate the role of ER81 in breast carcinogenesis, we examined ER81 expression in IDC, DCIS, ADH, HUT, and normal breast tissues by immunohistochemical staining. We found that ER81 overexpression was detected in 25.7% (9/35) of HUT, 41.2% (7/17) of ADH, 54.5% (12/22) of DCIS, and 63.0% (51/81) of IDC. In 20 of breast cancer tissues combined with DCIS, ADH, and HUT, ER81 expression was found in 14/20 (70%) IDC. In these 14 cases all cases were ER81 positive expression in DCIS, 13 of 14 cases were positively expressed of ER81 in ADH and 8 of 14 were positive for ER81 in HUT components. A statistical significance was found between NBT and HUT () and HUT and ADH (). Clinical-pathological features analysis of breast cancer revealed that ER81 expression was significantly associated with Her2 amplification and was negatively associated with ER and PR expression. Our results demonstrated that ER81 overexpression was present in the early stage of breast development that suggested that ER81 overexpression may play an important role in breast carcinogenesis.

Download Full-text

Potential role of long non-coding RNA LINC00968 in luminal A and B breast cancers

10.21203/rs.3.rs-59534/v2 ◽

2020 ◽

Author(s):

Maedeh Arabpour ◽

Sepideh Mehrpour Layeghi ◽

Keivan Majidzadeh-A ◽

Javad Tavakkoly bazzaz ◽

Ali Mamivand ◽

...

Keyword(s):

Breast Cancer ◽

Signaling Pathway ◽

Cell Lines ◽

Potential Role ◽

Tumor Stage ◽

Receptor Interaction ◽

Breast Cancers ◽

Luminal A ◽

Cancer Pathogenesis

Abstract Purpose Breast Cancer (BC) is the most frequent malignancy among women worldwide. ER+ breast cancers (luminal A and B subtypes) comprise up to 70% of all BC patients. Long non-coding RNAs (lncRNAs) are regulatory non-coding transcripts and longer than 200 nucleotides. LncRNAs can affect many biological and pathological processes and dysregulation of them is related to many human cancers. The potential role of LINC00968 lncRNA in luminal A and B breast cancer pathogenesis is still unclear. Methods Seventy-one pairs of tumor and adjacent non-tumor tissue specimens of luminal A and B breast cancer were used to analyze the expression of LINC00968. Furthermore, two luminal A cell lines, MCF7 and T47D, were used to evaluate the expression of LINC00968 compared with a non-malignant breast cell line, MCF10A. Moreover, we have done multiple bioinformatic analyses for a better understanding of the potential roles of LINC00968 in luminal BC. Results Our data revealed the significant downregulation of LINC00968 in luminal tumor tissues and cell lines. LINC00968 expression was negatively associated with tumor stage and lymph node metastasis. Bioinformatic analyses indicated that LINC00968 might be involved in blood vessel development, angiogenesis, and might be participated in interaction of ECM constituents with cancer cells. LINC00968 might have functions in some cancer-related signaling pathways, like PI3K/Akt, ECM-receptor interaction signaling pathway, and PPAR signaling pathway. Conclusions Downregulation of LINC00968 might promote carcinogenesis of luminal BC. LINC00968 might act as a tumor suppressor gene and might also promote invasion and metastasis of luminal BC.

Download Full-text

Potential Role of Chibby as a Tumor Suppressor in Breast Cancer

10.21236/ada441272 ◽

2005 ◽

Author(s):

Richard W. Carthew

Keyword(s):

Breast Cancer ◽

Tumor Suppressor ◽

Potential Role

Download Full-text

The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer

Journal of Oncology Pharmacy Practice ◽

10.1177/10781552211029361 ◽

2021 ◽

pp. 107815522110293

Author(s):

Amanda V Pirolli ◽

Tatiana Brusamarello ◽

Stella S Everton ◽

Vânia M S Andrzejevski

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Hormonal Therapy ◽

Clinical Pharmacist ◽

Tertiary Care ◽

Structured Interview ◽

Care Hospital ◽

Adjuvant Hormonal Therapy ◽

Breast Cancers

Breast cancer is the most prevalent type of cancer among women, affecting about 2.1 million worldwide and is responsible for the highest number of cancer-related deaths among women. Approximately 80% of breast cancers express on the surface of hormone receptor cells, such as progesterone and estrogen. In these cases, Adjuvant Hormonal Therapy (AHT) is indicated for a period of five to ten years and consists of taking a daily oral pill. The two most used drugs in AHT are tamoxifen and Aromatase Inhibitors. One of the issues most faced by individuals who are subjected to long periods of treatment is the lack of medication adherence and, consequently, therapeutic inefficiency. It is believed that the monitoring by the pharmacist can contribute to the reduction of errors inherent to the medication, making the treatment more effective and improving the patient's quality of life. The present study aimed to know the perception of patients who live with breast cancer and who do AHT in relation to the educational performance of the clinical pharmacist. This is a qualitative, descriptive and exploratory study, carried out from March to October 2020, with 15 women undergoing treatment at the oncology unit of a tertiary-care hospital in south of Brazil. The data were obtained through a semi-structured interview using an instrument composed of two parts, one referring to the characterization of the participants and the other with the guiding question of the research: "How do you perceive the role of the pharmacist in relation to the guidelines for the use of adjuvant hormonal therapy?". The method of theoretical saturation was used to perform the sample closure and the thematic analysis was used to analyze the data. The participants were between 32 and 74 years old, seven were on tamoxifen therapy and eight on anastrozole, ten were on the first year of treatment, two on the second and three on the third year. The themes that emerged were: pharmacist-patient interaction as a safety factor in hormone therapy; role of the pharmacist in the development of strategies for self-management of the patients during hormone therapy; and, challenges for the pharmacist in relation to hormone therapy through continued guidance. It was evident that the pharmacist's educational action encouraged the participants to carry out the treatment in a more confident and assertive manner according to their particularities and beliefs.

Download Full-text

The Roles of DNA Demethylases in Triple-Negative Breast Cancer

Pharmaceuticals ◽

10.3390/ph14070628 ◽

2021 ◽

Vol 14 (7) ◽

pp. 628

Author(s):

Shoghag Panjarian ◽

Jean-Pierre J. Issa

Keyword(s):

Breast Cancer ◽

Dna Methylation ◽

Tumor Suppressor Genes ◽

Hormone Receptors ◽

Triple Negative ◽

Breast Cancers ◽

Therapeutic Implications ◽

High Propensity ◽

Dna Methylation Profile

Triple-negative breast cancers (TNBCs) are very heterogenous, molecularly diverse, and are characterized by a high propensity to relapse or metastasize. Clinically, TNBC remains a diagnosis of exclusion by the lack of hormone receptors (Estrogen Receptor (ER) and Progesterone Receptor (PR)) as well as the absence of overexpression and/or amplification of HER2. DNA methylation plays an important role in breast cancer carcinogenesis and TNBCs have a distinct DNA methylation profile characterized by marked hypomethylation and lower gains of methylations compared to all other subtypes. DNA methylation is regulated by the balance of DNA methylases (DNMTs) and DNA demethylases (TETs). Here, we review the roles of TETs as context-dependent tumor-suppressor genes and/or oncogenes in solid tumors, and we discuss the current understandings of the oncogenic role of TET1 and its therapeutic implications in TNBCs.

Download Full-text

Oncogenic UBE3C promotes breast cancer progression by activating Wnt/β-catenin signaling

Cancer Cell International ◽

10.1186/s12935-020-01733-7 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Chen Hang ◽

Shanojie Zhao ◽

Tiejun Wang ◽

Yan Zhang

Keyword(s):

Breast Cancer ◽

Cancer Progression ◽

Nuclear Accumulation ◽

Migration And Invasion ◽

Ubiquitin Protein Ligase ◽

Novel Target ◽

First Time ◽

Breast Tissues

Abstract Background Breast cancer (BrCa) is the most common female malignancy worldwide and has the highest morbidity among all cancers in females. Unfortunately, the mechanisms of BrCa growth and metastasis, which lead to a poor prognosis in BrCa patients, have not been well characterized. Methods Immunohistochemistry (IHC) was performed on a BrCa tissue microarray (TMA) containing 80 samples to evaluate ubiquitin protein ligase E3C (UBE3C) expression. In addition, a series of cellular experiments were conducted to reveal the role of UBE3C in BrCa. Results In this research, we identified UBE3C as an oncogenic factor in BrCa growth and metastasis for the first time. UBE3C expression was upregulated in BrCa tissues compared with adjacent breast tissues. BrCa patients with high nuclear UBE3C expression in tumors showed remarkably worse overall survival (OS) than those with low nuclear expression. Knockdown of UBE3C expression in MCF-7 and MDA-MB-453 BrCa cells inhibited cell proliferation, migration and invasion in vitro, while overexpression of UBE3C in these cells exerted the opposite effects. Moreover, UBE3C promoted β-catenin nuclear accumulation, leading to the activation of the Wnt/β-catenin signaling pathway in BrCa cells. Conclusion Collectively, these results imply that UBE3C plays crucial roles in BrCa development and progression and that UBE3C may be a novel target for the prevention and treatment of BrCa.

Download Full-text

NEURAL CLASSIFICATION OF MASS ABNORMALITIES WITH DIFFERENT TYPES OF FEATURES IN DIGITAL MAMMOGRAPHY

International Journal of Computational Intelligence and Applications ◽

10.1142/s1469026806001757 ◽

2006 ◽

Vol 06 (01) ◽

pp. 61-75 ◽

Cited By ~ 15

Author(s):

R. PANCHAL ◽

B. VERMA

Keyword(s):

Breast Cancer ◽

Research Work ◽

Breast Cancer Diagnosis ◽

Classification Rate ◽

Test Dataset ◽

Benchmark Database ◽

Different Types ◽

Breast Tissues ◽

Mass Type

Early detection of breast abnormalities remains the primary prevention against breast cancer despite the advances in breast cancer diagnosis and treatment. Presence of mass in breast tissues is highly indicative of breast cancer. The research work presented in this paper investigates the significance of different types of features using proposed neural network based classification technique to classify mass type of breast abnormalities in digital mammograms into malignant and benign. 14 gray level based features, four BI-RADS features, patient age feature and subtlety value feature have been explored using the proposed research methodology to attain maximum classification on test dataset. The proposed research technique attained a 91% testing classification rate with a 100% training classification rate on digital mammograms taken from the DDSM benchmark database.

Download Full-text